Funded Grants

Toxic amyloid proteins are known to be a significant contributing factor in the development of Alzheimer’s disease.

The team wants to take a new breakthrough technology called Cyto-iGluSnFR (pronounced “sight-oh-eye-glue-sniffer”) and adapt it for the discovery of drugs to treat a variety of brain and eye diseases.

The blood-brain barrier (BBB) plays an essential role in protecting the brain from blood-borne diseases.

No medications exist that can stop or even slow the progression for Alzheimer Disease (AD).

Two diseases that show very different trajectories have nevertheless led researchers to identify dysfunction in a common brain network.

Each year, over 1,500 Canadians sustain an acute spinal cord injury (SCI), and join close to 40,000 across our nation living with one of the most physically and psychologically devastating of injuries.

Most mental disorders begin in adolescence; however, there are many gaps in our understanding of youth mental health.

Sight is the most precious sense, and patients suffering vision loss endure a devastating experience. Blindness often results from the gradual death of photoreceptors, the retinal cells that perceive light.

Repetitive transcranial magnetic stimulation (rTMS) is an effective treatment for patients with depression who have not responded to antidepressant medications.

Noninvasive brain stimulation is gaining acceptance as an alternate therapy for an increasing number of disorders, including major depression, schizophrenia, stroke and Parkinson’s disease.